REGISTER NOW!

Is twice-yearly* LEQVIO® right for your patients with ASCVD and other comorbidities?

START DATE: Tuesday, November 15, 2022

START TIME: 3:00 pm ET

DURATION: 60 MINUTES

ABSTRACT: At this event, you can:

• Learn how twice-yearly LEQVIO may benefit certain complex patients with ASCVD, such as those with multiple comorbidities, who are already on a maximally tolerated statin
• Explore how certain patients with ASCVD who have comorbidities such as metabolic syndrome or renal impairment may attain sustained LDL-C reduction, by going in depth with LEQVIO’s efficacy and safety data
• Participate in a live Q&A

If you've already registered for this event click here.

*After 2 initial doses.

ASCVD, atherosclerotic cardiovascular disease.

Speaker

The speaker is being paid by Novartis Pharmaceuticals Corporation (NPC) to conduct this presentation.